Feed / SYK

Stryker Corporation

SYK

Healthcare · 325.56 -6.5% today

Follow SYKAlerts

Jodie read · what matters now

Revenue increased 2.6% versus the comparable filing period.

The story is only the start. Jodie keeps watching the filing evidence, the companies connected to SYK, and whether its market group begins moving.

Latest storyNo Struct brief yetJodie is monitoring new filings.
Disclosed connections17 verified links14 additional receipts in Pro
Organic co-movement groupMedical Devices & Supplies · ParticipantDiscovered from trading behaviour, not sector labels · Open group →

Latest filing assessment · baseline

Fundamentals strengthened in the latest filing

10-Q filed 2026-05-11 against the comparable filing from 2025-05-02.

constructive
OperationsconstructiveEvidence score +2
liquidityneutralEvidence score 0
valuationpremium

What improved

  • Revenue increased 2.6% versus the comparable filing period.
  • Operating margin improved 1.3 percentage points.

What weakened

  • Gross margin fell 0.5 percentage points.

Filing receipts

“The key components of the change were: Gross Profit Percent Net Sales Three Months 2025 63.8 % Sales pricing 10 bps Volume and mix 10 bps Manufacturing and supply chain costs (200) bps Structural optimization and other special charges 70 bps Inventory stepped up to fair value 60 bps Three Months 2026 63.3 % Gross profit as a percentage of net sales in the three months 2026 decreased to 63.3% from 63.8% in 2025 driven by higher manufacturing and supply chain costs primarily due to idle production time related to the cybersecurity incident.”

“The increase in interest expense in the three months 2026 from 2025 was primarily due to 2025 debt issuances.”

“The key components of the change were: Operating Income Percent Net Sales MedSurg and Neurotechnology Orthopaedics Three Months 2025 24.8 % 30.4 % Sales pricing 20 bps 0 bps Volume 20 bps (10) bps Manufacturing and supply chain costs (220) bps (190) bps Research, development and engineering expenses (40) bps 40 bps Selling, general and administrative expenses (80) bps 130 bps Three Months 2026 21.8 % 30.1 % The decrease in MedSurg and Neurotechnology operating income as a percentage of net sales for the three months was primarily driven by higher manufacturing and supply chain costs due to idle production time related to the cybersecurity incident, higher selling, general and administrative...”

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.

Who this business touches

The relationships behind SYK

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

BAXBaxter International Inc.competitorFull receipt with Pro →
CNMDCONMED CorporationcompetitorFull receipt with Pro →

Depended on by

UFPT21.5% of UFPTcustomerFull receipt with Pro →

Filing peers

EWUFPT

Companies whose filings use similar operating language.

You can see the shape of the network here. Pro opens 14 more links, the original filing receipts, and alerts when connected names begin moving. See Pro →

What is moving around it

Live connections

SYK is currently a Participant in the organic co-movement group Medical Devices & Supplies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

Theme membership history

No durable theme membership has been observed for this name yet.